Date://
RE: Patient Name:
Policy Number / Health Card Number
Re: Request for funding for Peristeen® Anal Irrigation
Insurer:
Dear Insurer,
<name> was seen in clinic on/_/_ for assessment of bowel dysfunction due to</name>
neurogenic bowel issues caused by:
□ Spinal cord injury
<ul><li>Multiple Sclerosis</li><li>Other:</li></ul>
The assessment of his/her condition determined that the patient has experienced the following:
□ Faecal Incontinence □ Chronic Constipation
<name> has tried the following interventions: oral medication, enema, manual stimulation and structured bowel programs.</name>
Despite the use of these conventional therapies bowel management products and methods of patients' condition, my patient continues to experience excessive time and issues with constipation or incontinence which have had adverse effects on his/her quality of life. I believe that <name> will benefit from the use of Peristeen.</name>
Research has demonstrated the effectiveness of Peristeen Anal Irrigation in significantly reducing fecal incontinence and chronic constipation.*
Without Peristeen, neurogenical patients that fail conservative treatment may require surgical intervention to control the problem.
I have prescribed Peristeen Anal Irrigation for amonth period. I will follow-up with the client in clinic and his/her response to this change in treatment.
We therefore request funding for this product (see prescription in the back).
Sincerely,
Doctor:
<del></del>
Patient Benefit Publications
Reduces symptoms of constipation compared with conservative bowel management 1, 3 Reduces symptoms of faecal incontinence compared with conservative bowel management 1, 3 Reduces incidence of urinary tract infections 1 Improves patients' opinion of intestinal functionality compared with baseline 2 Improves symptom-related quality of life compared with conservative bowel management 1 Improves quality of life compared with baseline 2

Reduces time spent on bowel management compared with conservative bowel management

1, 2, 3

- Is well tolerated and has a good safety profile in the short and long term
- Is associated with lower total cost to society than conservative bowel management

1, 4, 5

a<sup>´</sup>

## \*References available upon request:

- 1. Christensen P, Bazzocchi G, Coggrave M, et al. A randomized, controlled trial of transanal irrigation versus conservative bowel management in spinal cordinjured patients. Gastroenterology 2006;131:738–747.
- 2. Del Popolo G, Mosiello G, Pilati C, et al. Treatment of neurogenic bowel dysfunction using transanal irrigation: a multicenter Italian study. Spinal Cord 2008;46:517–522.
- 3. Christensen P, Andreasen J, Ehlers L. Cost-effectiveness of transanal irrigation versus conservative bowel management for spinal cord injury patients. Spinal Cord 2009;47:138–143.
- 4. Faaborg PM, Christensen P, Kvitsau B, Buntzen S, Laurberg S, Krogh K. Long-term outcome and safety of transanal colonic irrigation for neurogenic bowel dysfunction. Spinal Cord 2009;47:545-549.
- 5. Christensen P, Krogh K, Buntzen S, Payandeh F, Laurberg S. Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence. Dis Colon Rectum 2009;52:286–292.

Doctor:	
Patient Information Label	
Patient information Labet	
R Adults  Peristeen system (#29121) Peristeen assessory unit (#29122) Peristeen rectal catheter (#29123) Other:	
Quantity	
Repeats	
Condition	
□ Quadriplegia □ Paraplegia □ Spina Bifida	
☐ Multiple Sclerosis ☐ Other:	
Additional	information

Signature			Date//		
reimbursement. As such, t expressed or implied, conce	he provider should verify cov	verage criteria and other priateness of this informati	payer requirements. Col on for any particular use	oplast Canada Corporation and this information is not i	ation communicated to the payer for makes no warranties or guarantees ntended to provide direction or advice entity.